SUNHO BIO‑B(02898.HK): Appoints ZZ Risk Management as Independent Internal Control Consultant; Shares Remain Suspended

NewTimeSpace News: Sunho Biologics, Inc.(02898.HK) issued an announcement on 4 August 2026. Pursuant to HKEX’s resumption guidance, the Company is required to engage an independent internal‑control consultant to carry out an independent internal‑control review, and demonstrate that identified material weaknesses have been rectified and that internal controls are adequate and effective. On 4 August 2026, following the recommendation from the Audit Committee, the Company appointed ZZ Risk Management Consulting Services Limited as the independent internal‑control consultant.

The independent internal‑control review will be conducted in three main phases: initial assessment to understand the existing framework; in‑depth review to identify weaknesses and propose remedial measures; follow‑up review to evaluate the effectiveness of remedial measures. The review scope will cover financial reporting, procurement, sales, cash management, prepayment management, R&D, outsourcing, contract management, Listing Rule compliance, and other material operational and governance processes.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.